The dramatic increase in revenues in 2017 to €12.8mln reflected a full year's contribution from sales of Lojuxta, which is used to treat the rare, life-threatening cholesterol disorder, HoFH.
More From BioPortfolio on "Amryt Pharma to tweak protocol for its epidermolysis bullosa phase III study"